Anti-Integrin a2b [M148]
Invented by Dr JOHN KEMSHEAD from SHIRE PHARMACEUTICALS
Invented at Institute Of Child Health
- Datasheet
- References (8)
- Inventor Info
Info
| Catalogue Number | 151128 |
| Applications | FACS IHC IF IP Fn |
| Antigen/Gene or Protein Targets | Integrin alpha 2b (CD41) |
| Synonyms | Integrin Subunit Alpha 2; Alpha 2 Subunit Of VLA-2 Receptor; Platelet Membrane Glycoprotein Ia; CD49 Antigen-Like Family Member B; Collagen Receptor; CD49B; GPIa; Very Late Activation Protein 2 Receptor, Alpha-2 Subunit; Human Platelet Alloantigen System 5; Platelet Glycoprotein GPIa; Platelet Antigen Br; VLA-2 Subunit Alpha; CD49b Antigen; HPA-5; VLA-2; VLAA2; BR |
| Reactivity | Human |
| Relevance | Integrins are heterodimeric cell surface receptors composed of alpha and beta subunits, which mediate cell-cell and cell-extracellular matrix attachments. Integrin alpha 2b (CD41) and integrin ß3 (CD61) associate to form the heterodimer integrin a2bß3 (CD41/CD61; GPIIb/IIIa), a fibronectin receptor expressed in platelets. M148 prevents aggregation of platelets. Used for imaging and therapy of thrombi. M148 binds to some medulloblastoma and neuroblastoma cells and rhabdomyosarcoma and certain other solid tumours. No binding is observed to marrow constituents other than platelets and megakaryocytes. Aberrant integrin expression has been found in many epithelial tumours. Changes in integrin expression have been shown to be important for the growth and early metastatic capacity of melanoma cells. |
| Host | Mouse |
| Immunogen | Homogenized human medulloblastoma tissue. |
| Positive Control | human platelets and megakaryocytes |
| Subclass | IgG1 |
| Molecular Weight (kDa) | 110-130 |
| Myeloma Used | P3X63Ag8.653 |
| Recommended Growing Conditions | DMEM + 5% FCS |
| Strain | Balb/c |
| Notes | M148 inhibits ADP-induced fibrinogen binding and platelet aggregation (Jones et al., 1984) |
| Research Area | Cancer |
References: 8 entries
Alonso-Orgaz et al. 2014. J Proteomics. 109:368-81. PMID: 25065646.
IHC
Proteomic characterization of human coronary thrombus in patients with ST-segment elevation acute myocardial infarction.
Europe PMC ID: 25065646
Cloutier et al. 2013. EMBO Mol Med. 5(2):235-49. PMID: 23165896.
The exposure of autoantigens by microparticles underlies the formation of potent inflammatory components: the microparticle-associated immune complexes.
Europe PMC ID: 23165896
Boilard et al. 2011. J Immunol. 186(7):4361-6. PMID: 21357261.
Platelets participate in synovitis via Cox-1-dependent synthesis of prostacyclin independently of microparticle generation.
Europe PMC ID: 21357261
Jones et al. 1984. Br J Haematol. 57(4):621-31. PMID: 6234927.
IF Fn
A monoclonal antibody binding to human medulloblastoma cells and to the platelet glycoprotein IIB-IIIA complex.
Europe PMC ID: 6234927
Add a reference
References: 8 entries
Alonso-Orgaz et al. 2014. J Proteomics. 109:368-81. PMID: 25065646.
IHC
Proteomic characterization of human coronary thrombus in patients with ST-segment elevation acute myocardial infarction.
Cloutier et al. 2013. EMBO Mol Med. 5(2):235-49. PMID: 23165896.
The exposure of autoantigens by microparticles underlies the formation of potent inflammatory components: the microparticle-associated immune complexes.
Boilard et al. 2011. J Immunol. 186(7):4361-6. PMID: 21357261.
Platelets participate in synovitis via Cox-1-dependent synthesis of prostacyclin independently of microparticle generation.
Jones et al. 1984. Br J Haematol. 57(4):621-31. PMID: 6234927.
IF Fn
A monoclonal antibody binding to human medulloblastoma cells and to the platelet glycoprotein IIB-IIIA complex.
Add a reference
